AG
CCCC icon

Algert Global’s C4 Therapeutics CCCC Stock Holding History

Algert Global’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Buy
+16,040
New +$54.9K ﹤0.01% 1229
2025
Q4 		– Sell
-106,300
Closed -$236K – 1160
2025
Q3 		$236K Buy
+106,300
New +$255K ﹤0.01% 1032
2024
Q1 		– Sell
-27,960
Closed -$158K – 1096
2023
Q4 		$158K Sell
27,960
-23,800
-46% -$54.3K 0.01% 1042
2023
Q3 		$96.3K Sell
51,760
-7,310
-12% -$22.3K ﹤0.01% 1035
2023
Q2 		$162K Buy
+59,070
New +$190K 0.01% 1003

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Algert Global's CCCC Position: Q2 2026 in Review

Algert Global opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 16,040 shares worth $74.9K. The stake represents ﹤0.01% of the portfolio and ranks #1229 among its holdings. This is a return to the name: Algert Global previously reported a position in CCCC as recently as Q3 2025.

Algert Global first reported a position in CCCC in Q2 2023 and has held it in 5 quarters since. The position peaked at $236K in Q3 2025. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Algert Global held 16,040 shares of C4 Therapeutics worth $74.9K as of Q2 2026.
  • C4 Therapeutics was a new Algert Global position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1229 holding.
  • Algert Global first reported a position in C4 Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • Algert Global's C4 Therapeutics position peaked at $236K in Q3 2025.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.